Molecular response to first line nilotinib in a patient with e19a2 BCR-ABL1 chronic myeloid leukemia

被引：9
|
作者：
Langabeer, Stephen E. [1 ]
McCarron, Sarah L.
Carroll, Peig
Kelly, Johanna [2 ]
O'Dwyer, Michael [3 ]
Conneally, Eibhlin [4 ]
机构：
[1] St James Hosp, Cent Pathol Lab, Dublin 8, Ireland
[2] Our Ladys Childrens Hosp, Natl Ctr Med Genet, Dublin, Ireland
[3] Natl Univ Ireland, Dept Haematol, Galway, Ireland
[4] St James Hosp, Dept Haematol, Dublin 8, Ireland
来源：
LEUKEMIA RESEARCH | 2011年 / 35卷 / 09期
关键词：
IMATINIB; MUTATION; DISEASE;
D O I：
10.1016/j.leukres.2011.05.010
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E169 / E170
页数：2
相关论文
共 50 条
  • [11] Distribution of BCR-ABL1 Transcript Variants in Nigerians with Chronic Myeloid Leukemia
    Owojuyigbe, Temilola O.
    Durosinmi, Muheez A.
    Bolarinwa, Ramoni A. A.
    Salawu, Lateef
    Akinola, Norah O.
    Ademosun, Abdulwaheed A.
    Bosede, Oluwayomi T.
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2020, 36 (04) : 646 - 651
  • [12] Asciminib: first FDA approved allosteric inhibitor of BCR-ABL1 for the treatment of chronic myeloid leukemia
    De, Surya K.
    MEDICINAL CHEMISTRY RESEARCH, 2023, 32 (03) : 424 - 433
  • [13] Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia
    Soverini, Simona
    de Benedittis, Caterina
    Mancini, Manuela
    Martinelli, Giovanni
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S120 - S128
  • [14] Guidelines for molecular monitoring of BCR-ABL1 in chronic myeloid leukemia patients by RT-qPCR
    Larripa, Irene
    Sol Ruiz, Maria
    Gutierrez, Marina
    Bianchini, Michele
    MEDICINA-BUENOS AIRES, 2017, 77 (01) : 61 - 72
  • [15] A Synergistic Combination Against Chronic Myeloid Leukemia: An Intra-molecular Mechanism of Communication in BCR-ABL1 Resistance
    El Rashedy, Ahmed A.
    Appiah-Kubi, Patrick
    Soliman, Mahmoud E. S.
    PROTEIN JOURNAL, 2019, 38 (02) : 142 - 150
  • [16] Nilotinib and allogeneic stem cell transplantation in a chronic myeloid leukemia patient with e6a2 and e1a2 BCR-ABL transcripts
    Langabeer, Stephen E.
    Crampe, Mireille
    Kelly, Johanna
    Fadalla, Kamal
    Connaghan, Gerard
    Conneally, Eibhlin
    LEUKEMIA RESEARCH, 2010, 34 (08) : E204 - E205
  • [17] BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR
    Zagaria, Antonella
    Anelli, Luisa
    Coccaro, Nicoletta
    Tota, Giuseppina
    Casieri, Paola
    Cellamare, Angelo
    Impera, Luciana
    Brunetti, Claudia
    Minervini, Angela
    Minervini, Crescenzio Francesco
    Delia, Mario
    Cumbo, Cosimo
    Orsini, Paola
    Specchia, Giorgina
    Albano, Francesco
    VIRCHOWS ARCHIV, 2015, 467 (03) : 357 - 363
  • [18] Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib
    Soverini, Simona
    Gnani, Alessandra
    De Benedittis, Caterina
    Castagnetti, Fausto
    Gugliotta, Gabriele
    Iacobucci, Ilaria
    Palandri, Francesca
    Rosti, Gianantonio
    Testoni, Nicoletta
    Luatti, Simona
    Marzocchi, Giulia
    Baccarani, Michele
    Martinelli, Giovanni
    LEUKEMIA RESEARCH, 2011, 35 (11) : 1527 - 1529
  • [19] Deep molecular responses achieved in chronic myeloid leukemia in chronic phase patients with BCR-ABL1 >10% at 3 months who are early switched to nilotinib
    Yue, Yanhua
    Gui, Xiaomin
    He, Xuefeng
    Chen, Yan
    Pan, Jinlan
    Qiu, Huiying
    Wu, Depei
    Chen, Suning
    Guo, Lingchuan
    Cen, Jiannong
    HEMATOLOGY, 2016, 21 (04) : 213 - 217
  • [20] Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients
    Arun, A. K.
    Senthamizhselvi, A.
    Mani, S.
    Vinodhini, K.
    Janet, N. B.
    Lakshmi, K. M.
    Abraham, A.
    George, B.
    Srivastava, A.
    Srivastava, V. M.
    Mathews, V.
    Balasubramanian, P.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2017, 39 (03) : 235 - 242
12345